SCHEMBL2329637

SCHEMBL2329637

CCOP(=O)(O)CC(=O)c1ccc(Cl)cc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
NR1I2 O75469 1/20 0.43
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
TP53 P04637 1/20 0.38
EGFR P00533 1/20 0.38
CYP11B2 P19099 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
RECQL P46063 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TSHR P16473 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
NPC1 O15118 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322162 0.87 KMT2A (0.53) TDP1KMT2AMEN1NR1I2SMN1; SMN2
SCHEMBL2322311 0.86 SMN1; SMN2 (0.44) KMT2AMEN1TP53SMN1; SMN2NPC1
SCHEMBL2324765 0.84 TAS1R3 (0.47) TDP1KMT2AMEN1NR1I2TP53
SCHEMBL2325155 0.83 TSHR (0.36) TDP1KMT2AMEN1SMN1; SMN2POLB
SCHEMBL1549244 0.80 KMT2A (0.48) KMT2AMEN1SMN1; SMN2POLBTHRB
SCHEMBL1549852 0.79 HTT (0.41) TDP1KMT2AMEN1NR1I2TP53
SCHEMBL2329635 0.78 FLT1 (0.43) FLT1FLT4KDRCYP11B2SMN1; SMN2
SCHEMBL2322882 0.77 KMT2A (0.49) KMT2AMEN1TP53SMN1; SMN2POLB
SCHEMBL5733473 0.77 SUCNR1 (0.48) KMT2AMEN1SMN1; SMN2POLBTHRB
SCHEMBL1549681 0.77 KMT2A (0.42) TDP1KMT2AMEN1NR1I2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 TDP1 913/4885KMT2A 2891/4885MEN1 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.